
800.00
700.00
600.00
500.00
400.00
300.00
200.00
100.00
0.00
Tumor volume (mm3)
0 2 5 7 9 12 14 16 19 21 23 26 28 30 33
Days
Vehicle
5 FU 40 mg/kg
I-3 5 mg/kg M, W, F
I-3 15 mg/kg M, W, F
I-3 25 mg/kg M,W, F
I-3 25 mg/kg M, T

FIG. 1



FIG. 2A



FIG. 2B



FIG. 2C


MDA-MB-468 TNBC (IC50 10nM)
0 5 10 50 100 250 500 1uM 10uM
MCL-1
IKB-P
IkB
Cyclin D1
Cyclin B1
Cyclin D3
CDK6
pRB
pRB-P
Actin
HS578T TNBC (IC50 1.5 µM)
0 5 10 50 100 250 500 1uM 10uM

FIG. 3


Weight (g)
25
24
23
22
21
20
19
18
17
0
4
5
6
7
8
10
12
Study Day
Dexamethasone 1 mg/kg
I-4 15 mg/kg
I-4 4 mg/kg
I-4 7.5 mg/kg
Vehicle

FIG. 4


Total Score
14
12
10
8
6
4
2
0
0
4
5
6
7
8
10
12
Study Day
Dexamethasone 1 mg/kg
I-4 15 mg/kg
I-4 4 mg/kg
I-4 7.5 mg/kg
Vehicle

FIG. 5


Scaling
Erythema
Thickness
Scaling, Erythema Score, Thickness (mm)
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Naive
PMA - Vehicle
I-4 10 mg/kg Oral
betamethasone

FIG. 6


Novel Object Recognition - Index of discrimination D1 (b-a)
D1 (sec)
15
12
9
6
3
0
Lean VEH
Obese VEH
0.625
1.25
2.5
Treatment group


Novel Object Recognition - Index of discrimination D2 (D1/a+b)
D2
1.0
0.8
0.6
0.4
0.2
0.0
Lean VEH
Obese VEH
0.625
1.25
2.5
Treatment group

FIG. 7


2.5 mg/kg x 5 day: Cummulative Food Intake
Cummulative Food Intake (g)
Zucker fa/fa control
Zucker lean control
Zucker fa/fa KPT I-4 2.5 mg/kg
Baseline
Treatment
W/O
Study Day
2.5 mg/kg x 5 day: Average Food Intake
Food intake (g)
Study Day

FIG. 8A


2.5 mg/kg x 5 day: Average Body Weight
Body Weight (g)
Zucker fa/fa control
Zucker lean control
Zucker fa/fa KPT I-4 2.5 mg/kg
Baseline
Treatment
W/O
Study Day
2.5 mg/kg x 5 day: Body Weight change
Body Weight to baseline (%)
Study Day

FIG. 8B